Christina S. Meade
Associate Professor in Psychiatry and Behavioral Sciences
Overview
Dr. Meade’s domestic research program focuses on predictors of HIV risk behavior in adults with substance use and psychiatric disorders, and the relationship between neuropsychiatric conditions and continued risk behavior in HIV-positive adults. She is particularly interested in how drug addiction and HIV infection impact executive functions, such as decision making, that lead individuals to engage in risky behaviors. Many of her current projects incorporate MRI to isolate the effects of addiction and HIV on both brain function and structure. Dr. Meade is also interested in the development of evidence-based treatments to improve cognitive functioning and reduce risk behaviors among drug users.
Given that most people infected or affected by HIV/AIDS live in Sub-Saharan Africa, Dr. Meade’s international research program is based in South Africa. The Western Cape has experienced a dramatic increase in methamphetamine use since the early 2000s, and there is concern that it may further fuel the HIV epidemic in this country. Current projects focus on characterizing drug addiction and HIV risk behaviors in this understudied group, both in in community and treatment settings, and ultimately increasing uptake of HIV services to improve health outcomes and reduce the continued spread of HIV.
Selected Grants
Modeling the effects of chronic marijuana use on neuroinflammation and HIV-related neuronal injury awarded by National Institutes of Health (Principal Investigator). 2020 to 2025
Interdisciplinary Research Training Program in AIDS awarded by National Institutes of Health (Mentor). 2010 to 2025
Role of cannabis on HIV-related cognitive impairment: a brain connectomics study awarded by National Institutes of Health (Principal Investigator). 2018 to 2023
MRI data fusion to investigate effects of drug abuse on HIV neurological complications awarded by National Institutes of Health (Principal Investigator). 2018 to 2023
Mobile health interventions for varenicline adherence among HIV-positive smokers awarded by National Institutes of Health (Co-Mentor). 2017 to 2022
A Systems Biology Approach to HIV-associated Neurocognitive Impairment: Role of Drug Abuse and Neuroinflammation awarded by National Institutes of Health (Co-Principal Investigator). 2016 to 2021
Decision Making and HIV Risk: New Approaches to neuroAIDS Research in Drug Users awarded by National Institutes of Health (Principal Investigator). 2015 to 2020
Testing a Biopsychosocial Model of Minority Stress and Health for HIV-Positive Men awarded by Research Foundation of The City University of New York (Principal Investigator). 2019 to 2020
Cognitive Training to Reduce Impulsivity in HIV-infected Cocaine Users awarded by National Institutes of Health (Principal Investigator). 2016 to 2019
NeuroAIDS research with disadvantaged drug users awarded by National Institutes of Health (Principal Investigator). 2014 to 2017
Pages
Miles, M. S., et al. “Emotional distress in african american women with hiv.” HIV: Issues with Mental Health and Illness, 2014, pp. 35–50. Scopus, doi:10.4324/9781315785509. Full Text
Sikkema, Kathleen J., et al. Community-level HIV prevention for persons with severe mental illness living in supportive housing programs: a pilot intervention study. Vol. 33, 2007, pp. 121–35. Pubmed, doi:10.1300/J005v33n01_10. Full Text
Hall, Shana A., et al. “Synergistic effects of HIV and marijuana use on functional brain network organization.” Prog Neuropsychopharmacol Biol Psychiatry, vol. 104, Jan. 2021, p. 110040. Pubmed, doi:10.1016/j.pnpbp.2020.110040. Full Text
Towe, Sheri L., et al. “Reciprocal Influences of HIV and Cannabinoids on the Brain and Cognitive Function.” J Neuroimmune Pharmacol, vol. 15, no. 4, Dec. 2020, pp. 765–79. Pubmed, doi:10.1007/s11481-020-09921-y. Full Text
Tamargo, Javier A., et al. “Cognitive Impairment among People Who Use Heroin and Fentanyl: Findings from the Miami Adult Studies on HIV (MASH) Cohort.” J Psychoactive Drugs, Nov. 2020, pp. 1–9. Pubmed, doi:10.1080/02791072.2020.1850946. Full Text
Lee, Jared, et al. “Tryptophan degradation is associated with risk-taking propensity in methamphetamine users with treated HIV infection.” J Neurovirol, vol. 26, no. 5, Oct. 2020, pp. 779–84. Pubmed, doi:10.1007/s13365-020-00841-4. Full Text
Xu, Yunan, et al. “Effects of substance use on monetary delay discounting among people who use stimulants with and without HIV: An ecological momentary assessment study.” Exp Clin Psychopharmacol, Aug. 2020. Pubmed, doi:10.1037/pha0000423. Full Text
Towe, Sheri L., et al. “Examining the Potential of Pre-exposure Prophylaxis (PrEP) for HIV Prevention in a Community Sample of Persons Who Use Stimulants Living in the Southern United States.” Aids Behav, Aug. 2020. Pubmed, doi:10.1007/s10461-020-02987-y. Full Text
Towe, Sheri L., et al. “Web-Based Cognitive Training to Improve Working Memory in Persons with Co-Occurring HIV Infection and Cocaine Use Disorder: Outcomes from a Randomized Controlled Trial.” Aids Behav, Aug. 2020. Pubmed, doi:10.1007/s10461-020-02993-0. Full Text
Meade, Christina S., et al. “HIV Prevalence and Associated Risks in a Respondent-Driven Sample of Illicit Stimulant Users in a Southern United States City.” Aids Behav, vol. 24, no. 8, Aug. 2020, pp. 2336–46. Pubmed, doi:10.1007/s10461-020-02793-6. Full Text
Bell, Ryan P., et al. “Neural sensitivity to risk in adults with co-occurring HIV infection and cocaine use disorder.” Cogn Affect Behav Neurosci, vol. 20, no. 4, Aug. 2020, pp. 859–72. Pubmed, doi:10.3758/s13415-020-00806-4. Full Text
Pacek, Lauren R., et al. “Cigarette Smoking and Cessation-Related Interactions With Health Care Providers in the Context of Living With HIV: Focus Group Study Findings.” J Assoc Nurses Aids Care, July 2020. Pubmed, doi:10.1097/JNC.0000000000000185. Full Text Open Access Copy
Pages
Hobkirk, Andrea L., et al. “FOOD INSECURITY IS ASSOCIATED WITH NEUROCOGNITIVE IMPAIRMENT AMONG INDIVIDUALS LIVING WITH HIV.” Annals of Behavioral Medicine, vol. 50, OXFORD UNIV PRESS INC, 2016, pp. S246–S246.